UK-headquartered QED Clinical Services, recently, enhanced its global delivery of clinical trials by creating a wholly owned subsidiary - QED Clinical Services India - in Ahmedabad, India. This expands QED's capacity and capabilities to offer global coverage to continue to successfully deliver high quality, cost effective projects. Mr Thomas Ogorka, CEO, QED Clinical Services talks to BioSpectrum about company's expansion in India.

Can you please elaborate on the work that will be undertaken at QED clinical India?

Mr Ogorka: India is not only perceived as a key location for service provision in the Asia Pacific region, but also as a component that contributes to the delivery of global services. QED is excited to offer better access to proven skills in delivery, a significant patient population that can contribute to global studies and the chance of better access to new medicine for the local population. QED offers its customers access to:
clinical monitoring and management; project management; regulatory affairs and regulatory consulting; site management and site support services; feasibility and site identification; patient recruitment and retention services; safety and pharmacovigilance; data management; and market registration for imported products.

What inspired you to choose India over other Asia Pacific countries to locate a subsidiary?

Mr Ogorka: India is perceived as a "must have" capability in the eye of the pharmaceutical industry. Besides, local market understanding is the best way to access the talents of the development team as well as the patients. With a huge patient pool (17 percent of global population with 20 percent of global disease burden), and a balance of treatment, naïve patients on one hand and high standards of care on the other, there are extensive capabilities to meet different study needs, rapid recruitment, world class infrastructure, facilities and trained manpower.